EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Elecsys pTau217 plasma immunoassay detection of amyloid pathology in clinical cohorts

Derrek P Hibar, Alina Bauer, Christina Rabe, Niels Borlinghaus, Alexander Jethwa, Gwendlyn Kollmorgen, Annunziata Di Domenico, Henrik Zetterberg, Kaj Blennow, Colin L Masters, Reisa A Sperling, Tobias Bittner iD

Alzheimer's & Dementia · 2026-01 · 22 (1)

DOI: 10.1002/alz.71009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 15.01.2026. Verfasst von Derrek P Hibar und 11 weiteren Autor:innen. Beteiligte Einrichtung: Genentech, Inc., South San Francisco, California, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, Cognitive Dysfunction, tau Proteins. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Research Council, European Union's Horizon Europe Research and Innovation Programme, Swedish State Support for Clinical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION We evaluated the clinical performance of the fully automated, high‐throughput, prototype Elecsys ® Phospho‐Tau (217P) plasma immunoassay (Roche Diagnostics) for detecting amyloid pathology. METHODS Plasma tau phosphorylated at threonine 217 (pTau217) levels were determined in samples from cognitively impaired and unimpaired individuals from five cohorts ( N = 2148) using the pTau217 plasma immunoassay. Clinical performance was evaluated against amyloid positron emission tomography. RESULTS For cognitively impaired, mean plasma pTau217 levels for amyloid‐positive (A+) individuals were higher ( n = 394; 0.835 pg/mL) than amyloid‐negative (A–) individuals ( n = 144; 0.361 pg/mL); similarly, for cognitively unimpaired, A+ ( n = 224; 0.516 pg/mL) and A– individuals ( n = 1386; 0.220 pg/mL). Area under the curve was 0.878 (95% confidence interval [CI] 0.840, 0.915; impaired) and 0.907 (95% CI 0.885, 0.929; unimpaired). A cutoff < 0.189 pg/mL reliably ruled out individuals without amyloid pathology. High negative predictive values (92.51% [impaired]; 98.60% [unimpaired]) were observed with sensitivity/specificity of 98.98%/29.17% and 95.54%/50.72%, respectively. DISCUSSION The pTau217 plasma immunoassay accurately detects amyloid pathology, irrespective of cognitive status. TRIAL REGISTRATION NUMBER A4, NCT02008357; SKYLINE, NCT05256134; AIBL, SAGE Project ID Number: 2022/PID06188; SVHM Local Ref ID: HREC 028/06; CREAD, NCT02670083; CREAD2, NCT03114657 Highlights The Elecsys ® pTau217 plasma immunoassay (Roche Diagnostics) was evaluated across five cohorts. The pTau217 plasma immunoassay demonstrated high performance in detecting amyloid pathology in both cognitively impaired and unimpaired individuals. The pTau217 plasma immunoassay had a high negative predictive value which supports its utility as a pre‐screening tool for Alzheimer's disease (AD). The pTau217 plasma immunoassay cutoffs identified are suitable for use as rule‐out pre‐screener tools in clinical trials. These findings reinforce the value of the high‐throughput pTau217 plasma immunoassay measurements to aid AD diagnosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAmyloid beta-PeptidesCognitive Dysfunctiontau ProteinsAgedAged, 80 and overFemaleHumansMaleMiddle AgedBiomarkersCohort StudiesImmunoassayPhosphorylationPositron-Emission TomographyMulticenter Studies as TopicRandomized Controlled Trials as TopicClinical Trials, Phase III as Topic

Stichwörter der Autor:innen

Alzheimer's diseaseamyloid pathologyblood‐based biomarkerscognitive declinedementiaimmunoassayplasmaplasma tau phosphorylated at threonine 217pre‐screeningsecondary prevention

Substanzen

Amyloid beta-PeptidesBiomarkerstau Proteins

Autor:innen und Institutionen

  • Genentech, Inc., South San Francisco, California, USA.
  • Roche Diagnostics GmbH, Penzberg, Germany.
  • Roche Diagnostics International Ltd, Rotkreuz, Switzerland.
  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
  • Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.

ORCID-Profile: Tobias Bittner

Förderung

  • Swedish Research Council
  • European Union's Horizon Europe Research and Innovation Programme
  • Swedish State Support for Clinical Research
  • F. Hoffmann-La Roche Ltd.
  • Vetenskapsrådet
  • F. Hoffmann-La Roche

Zitieren

APA

Hibar, D. P., Bauer, A., Rabe, C., Borlinghaus, N., Jethwa, A., Kollmorgen, G., Di Domenico, A., Zetterberg, H., Blennow, K., Masters, C. L., Sperling, R. A., & Bittner, T. (2026). Elecsys pTau217 plasma immunoassay detection of amyloid pathology in clinical cohorts. Alzheimer's & Dementia, 22(1). https://doi.org/10.1002/alz.71009

Vancouver

Hibar DP, Bauer A, Rabe C, Borlinghaus N, Jethwa A, Kollmorgen G, et al. Elecsys pTau217 plasma immunoassay detection of amyloid pathology in clinical cohorts. Alzheimer's & Dementia. 2026;22(1). doi:10.1002/alz.71009

BibTeX
@article{Hibar2026,
  author = {Hibar, Derrek P and Bauer, Alina and Rabe, Christina and Borlinghaus, Niels and Jethwa, Alexander and Kollmorgen, Gwendlyn and Di Domenico, Annunziata and Zetterberg, Henrik and Blennow, Kaj and Masters, Colin L and Sperling, Reisa A and Bittner, Tobias},
  title = {Elecsys pTau217 plasma immunoassay detection of amyloid pathology in clinical cohorts},
  journal = {Alzheimer's & Dementia},
  year = {2026},
  volume = {22},
  number = {1},
  doi = {10.1002/alz.71009}
}
Kostenlos starten →